Step closer to nasal spray drug delivery for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.
Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.
Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed. Advanced Science
Release date: 24 May 2021
Source: University of York